科兴集团：流感防控，预防是关键

Group 1: Influenza Vaccine Product Line - The company has a diverse product line of influenza vaccines, providing strong support for global influenza prevention [1] - Anlai Fu is China's first preservative-free trivalent influenza vaccine, suitable for all age groups from 6 months and older [1] - The company has administered over 100 million doses of its influenza vaccines across nearly 20 countries and regions [1] Group 2: Quality and Safety - The vaccines are free from preservatives and meet quality standards that exceed both Chinese and European pharmacopoeias [2][3] - The internal quality control standards have double the number of testing items compared to the Chinese pharmacopoeia [3] - Clinical studies indicate that the quadrivalent influenza vaccine has a seroprotection rate of up to 99.4% in China [6] Group 3: Immunogenicity and Efficacy - International multi-center clinical research shows that the immunogenicity of the quadrivalent influenza vaccine is significantly higher than that of similar international products [5] - Extensive research evidence supports the good safety profile of the quadrivalent and trivalent influenza vaccines, making them a reliable choice for vaccination [7][8] Group 4: Vaccination Strategy and Recommendations - The company emphasizes the importance of annual vaccination as a key strategy for influenza prevention, especially during the flu season [8] - It is recommended that all individuals aged 6 months and older, without contraindications, receive the influenza vaccine annually [17]